Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 18, Issue 9, Pages 861-872Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2018.1491795
Keywords
Fibroblast growth factor; fibroblast growth factor receptor; cancer; tyrosine kinase inhibitors; monoclonal antibodies; FGF traps
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 18943, MFAG 18459]
- Fondazione Cariplo grant [2016-0570]
Ask authors/readers for more resources
Introduction: Deregulation of the fibroblast growth factor (FGF)/FGF receptor (FGFR) network occurs frequently in tumors due to gene amplification, activating mutations, and oncogenic fusions. Thus, the development of FGF/FGFR-targeting therapies is the focus of several basic, preclinical, and clinical studies.Areas covered: This review will recapitulate the status of current FGF/FGFR-targeted drugs.Expert commentary: Non-selective FGF/FGFR inhibitors have been approved for cancer treatment but evidence highlights various complications affecting their use in the clinical practice. It appears mandatory to identify FGF/FGFR alterations and appropriate biomarkers that may predict and monitor response to treatment, to establish the contribution of the FGF/FGFR system to the onset of mechanisms of drug resistance, and to develop effective combinations of FGF/FGFR inhibitors with other targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available